{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:39:07Z","timestamp":1792471147510,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100032626","name":"Unitaid","doi-asserted-by":"publisher","award":["2017-21-Wits-PrEP"],"award-info":[{"award-number":["2017-21-Wits-PrEP"]}],"id":[{"id":"10.13039\/100032626","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032626","name":"Unitaid","doi-asserted-by":"publisher","award":["2017-21-Wits-PrEP"],"award-info":[{"award-number":["2017-21-Wits-PrEP"]}],"id":[{"id":"10.13039\/100032626","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-14082-z","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:35:23Z","timestamp":1784799323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The LEN4PrEP study: protocol for a phase 3B, non-randomised clinical trial integrating lenacapavir PrEP within multi-product HIV prevention services in primary care clinics in South Africa"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0409-9549","authenticated-orcid":false,"given":"Roisin E.","family":"Drysdale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine E.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinmayee","family":"Dhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siphokazi","family":"Dada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maletsatsi","family":"Monametsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nthabiseng","family":"Koloane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vusile","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius","family":"Nattey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiqa","family":"Mullick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"14082_CR1","unstructured":"AVAC. Global PrEP Tracker. 2026 Available from: https:\/\/data.prepwatch.org\/."},{"key":"14082_CR2","unstructured":"UNAIDS. The urgency of now: AIDS at a crossroads. Geneva; 2024."},{"issue":"13","key":"14082_CR3","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","volume":"391","author":"LG Bekker","year":"2024","unstructured":"Bekker LG, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, et al. Twice-Yearly Lenacapavir or Daily F\/TAF for HIV Prevention in Cisgender Women. N Engl J Med. 2024;391(13):1179\u201392.","journal-title":"N Engl J Med"},{"issue":"13","key":"14082_CR4","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","volume":"392","author":"CF Kelley","year":"2025","unstructured":"Kelley CF, Acevedo-Qui\u00f1ones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, et al. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. N Engl J Med. 2025;392(13):1261\u201376.","journal-title":"N Engl J Med"},{"issue":"11","key":"14082_CR5","doi-asserted-by":"publisher","first-page":"e736","DOI":"10.1016\/S2352-3018(24)00235-2","volume":"11","author":"MR Kamya","year":"2024","unstructured":"Kamya MR, Balzer LB, Ayieko J, Kabami J, Kakande E, Chamie G, et al. Dynamic choice HIV prevention with cabotegravir long-acting injectable in rural Uganda and Kenya: a randomised trial extension. Lancet HIV. 2024;11(11):e736\u201345.","journal-title":"Lancet HIV"},{"key":"14082_CR6","unstructured":"Naidoo N, Conlon M, Lee M, Akello C, Eichleay M, Irungu E, et al. editors. Expanding the PrEP Market: Early Insights Offering Oral, Ring, and CAB PrEP in Sub-Saharan Africa. CROI; San Fransisco, California; 2025 March 9\u201312."},{"key":"14082_CR7","unstructured":"Mullick S. Lessons learned from the implementation of LA PrEP: implications for rapid LEN introduction. 13th IAS Conference on HIV Science; Kigali, Rwanda; 2025."},{"issue":"6","key":"14082_CR8","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/j.jadohealth.2023.08.004","volume":"73","author":"CE Martin","year":"2023","unstructured":"Martin CE, Cox LA, Nongena P, Butler V, Ncube S, Sawry S, et al. Patterns of HIV Pre-exposure Prophylaxis use Among Adolescent Girls and Young Women Accessing Routine Sexual and Reproductive Health services in South Africa. J Adolesc Health. 2023;73(6):S81\u201391.","journal-title":"J Adolesc Health"},{"issue":"3","key":"14082_CR9","first-page":"e20210963","volume":"76","author":"M Antonini","year":"2023","unstructured":"Antonini M, Silva IED, Elias HC, Gerin L, Oliveira AC, Reis RK. Barriers to Pre-Exposure Prophylaxis (PrEP) use for HIV: an integrative review. Rev Bras Enferm. 2023;76(3):e20210963.","journal-title":"Rev Bras Enferm"},{"key":"14082_CR10","unstructured":"AVAC. From clinical trial efficacy to public health impact: a plan for accelerating access to injectable lenacapavir for PrEP. AVAC; 2024 Oct 2024."},{"issue":"3","key":"14082_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/MLR.0b013e3182408812","volume":"50","author":"GM Curran","year":"2012","unstructured":"Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012;50(3):217\u201326.","journal-title":"Med Care"},{"issue":"1","key":"14082_CR12","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2352-3018(25)00229-2","volume":"13","author":"CE Martin","year":"2026","unstructured":"Martin CE, Ramatsoma H, Chidumwa G, Nongena P, Letsielo MJ, Kutywayo A, et al. Uptake of dapivirine vaginal ring and oral pre-exposure prophylaxis among women accessing HIV prevention services in South Africa: a cohort study. Lancet HIV. 2026;13(1):e21\u20139.","journal-title":"Lancet HIV"},{"key":"14082_CR13","unstructured":"NDoH. National HIV testing servcies. Policy Pretoria National Department of Health. 2025."},{"key":"14082_CR14","volume-title":"Pre-Exposure Prophylaxis (PrEP): Lenacapavir Implementation Guidelines","author":"NDoH","year":"2025","unstructured":"NDoH. Pre-Exposure Prophylaxis (PrEP): Lenacapavir Implementation Guidelines. Pretoria: National Department of Health; 2025."},{"key":"14082_CR15","unstructured":"NDoH. 2021 updated guidelines for the provision of oral pre-exposure prophylaxis (PrEP) to persons at substantial risk of HIV infection pretoria: national department of health. 2021."},{"key":"14082_CR16","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208.","journal-title":"J Biomed Inform"},{"issue":"2","key":"14082_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"14082_CR18","unstructured":"RE-AIM. RE-AIM: improving public health relevance and population health impact 2023 [26 May 2023]. Available from: https:\/\/re-aim.org\/learn\/what-is-re-aim\/."},{"issue":"11","key":"14082_CR19","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.2105\/AJPH.2009.190959","volume":"100","author":"DK King","year":"2010","unstructured":"King DK, Glasgow RE, Leeman-Castillo B, Reaiming. RE-AIM: using the model to plan, implement, and evaluate the effects of environmental change approaches to enhancing population health. Am J Public Health. 2010;100(11):2076\u201384.","journal-title":"Am J Public Health"},{"key":"14082_CR20","unstructured":"Smith JA, Braun V, Clarke V, Hayfield N. Thematic analysis: a reflexive approach. 4th Ed."},{"key":"14082_CR21","unstructured":"SAHPRA Registers Lenacapavir. [press release]. Pretoria 27 Oct 2025."},{"key":"14082_CR22","unstructured":"President Ramaphosa to launch rollout of new HIV injection [press release]. Pretoria The Presidency, Republic of South Africa, 29 May 2026."},{"key":"14082_CR23","unstructured":"U.S. Department of Health and Human Services NIoH, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. Bethesda, MD; 2017."},{"issue":"6s","key":"14082_CR24","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/j.jadohealth.2023.08.003","volume":"73","author":"E Briedenhann","year":"2023","unstructured":"Briedenhann E, Rosenberg P, Sheobalak N, Pleaner M, Martin CE, Mullick S. Eita! Reaching Communities and Young People to Drive Demand for Oral Pre-Exposure Prophylaxis in South Africa. J Adolesc Health. 2023;73(6s):S50\u20137.","journal-title":"J Adolesc Health"},{"key":"14082_CR25","doi-asserted-by":"publisher","first-page":"1512429","DOI":"10.3389\/fpubh.2025.1512429","volume":"13","author":"V Costa","year":"2025","unstructured":"Costa V, Custodio MG, Gefen E, Fregni F. The relevance of the real-world evidence in research, clinical, and regulatory decision making. Front Public Health. 2025;13:1512429.","journal-title":"Front Public Health"},{"key":"14082_CR26","unstructured":"PURPOSE Studies. PURPOSE: Prevention with PURPOSE. 2026. Available from: https:\/\/www.purposestudies.com\/."},{"key":"14082_CR27","volume-title":"Twice-Yearly Subcutaneous Lenacapavir for PrEP: Updated HIV-1 Incidence and Safety Data in PURPOSE 1","author":"N Ndlovu","year":"2026","unstructured":"Ndlovu N, Malahleha M, Singh Y, Kiweewa F, Puryear S, Kintu A, et al. Twice-Yearly Subcutaneous Lenacapavir for PrEP: Updated HIV-1 Incidence and Safety Data in PURPOSE 1. San Diego, California: CROI; 2026."},{"key":"14082_CR28","volume-title":"Lenacapavir for PrEP: HIV-1 Incidence and Safety From PURPOSE 2 at End of Randomized Blinded Phase","author":"V Lucio","year":"2026","unstructured":"Lucio V, Mngadi K, Supparatpinyo K, Ndlovu N, Hinojosa J, Losso M, et al. Lenacapavir for PrEP: HIV-1 Incidence and Safety From PURPOSE 2 at End of Randomized Blinded Phase. San Diego, California: CROI; 2026."},{"key":"14082_CR29","volume-title":"Resistance Analyses of the PURPOSE Studies Through the End of the Randomized Blinded Phase","author":"S Cox","year":"2026","unstructured":"Cox S, Andreatta K, Hendricks M, Li J, Puryear S, Hojilla J, et al. Resistance Analyses of the PURPOSE Studies Through the End of the Randomized Blinded Phase. San Diego, California: CROI; 2026."},{"key":"14082_CR30","unstructured":"Bekker LG, Moodley D, Harkoo I, Kigozi G, Louw C, Malahleha M, et al. editors. Inclusion of pregnant and lactating people in the PURPOSE 1 study: efficacy, safety, and pharmacokinetics. 13th international AIDS society (IAS) conference on HIV science; 2025 July 13\u201317; Kigali, Rwanda."},{"issue":"1","key":"14082_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/infdis\/jiy113","volume":"218","author":"KA Thomson","year":"2018","unstructured":"Thomson KA, Hughes J, Baeten JM, John-Stewart G, Celum C, Cohen CR, et al. Increased Risk of HIV Acquisition Among Women Throughout Pregnancy and During the Postpartum Period: A Prospective Per-Coital-Act Analysis Among Women With HIV-Infected Partners. J Infect Dis. 2018;218(1):16\u201325.","journal-title":"J Infect Dis"},{"issue":"1","key":"14082_CR32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10461-024-04519-4","volume":"29","author":"CE Martin","year":"2025","unstructured":"Martin CE, Blaauw D, Nongena P, Chidumwa G, Dada S, Jack S, et al. Preferences for Delivery of HIV Prevention Services Among Healthcare Users in South Africa: A Discrete Choice Experiment. AIDS Behav. 2025;29(1):331\u201341.","journal-title":"AIDS Behav"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-14082-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14082-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14082-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:56:40Z","timestamp":1792468600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-14082-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14082"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-14082-z","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"1 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval has been granted by the University of the Witwatersrand Human Research Ethics Committee (250610) and the WHO Ethics Review Committee (ERC.0004293). The study has also been reviewed and approved by SAHPRA (20250610) and the Tshwane District Department of Health (GP_202509_064). The manufacturer of L4P (Gilead Sciences) reviewed and approved the protocol (CO-US-974-7718). Written informed consent will be obtained from all participants prior to commencement of study activities. Written parental consent and participant assent will be obtained from those aged between 16 and 17 years. Participation in the study is voluntary and those that decline consent or choose to withdraw will be able to continue receiving comprehensive health care services, including access to standard of care PrEP services, at the study sites. After each study visit, participants will receive reimbursement to cover their time and travel. All participant information will be protected to the fullest extent possible. Participants will not be named in any report, presentation or publication resulting from this study. Their data will not be shared without their explicit permission, and this will be detailed during the consenting process. Only delegated study staff will have access to participant identifiable information. All study procedures will be conducted in accordance with the Declaration of Helsinki and the South Africa Good Clinical Practice Clinical Trial Guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1833"}}